Literature DB >> 10450861

Clinical, biochemical, and molecular characterization of patients with glutathione synthetase deficiency.

E Al-Jishi1, B F Meyer, M S Rashed, M Al-Essa, M H Al-Hamed, N Sakati, S Sanjad, P T Ozand, M Kambouris.   

Abstract

Pyroglutamic aciduria (5-oxoprolinuria) is a rare autosomal recessive disorder caused by either glutathione synthetase deficiency (GSSD) or 5-oxoprolinase deficiency. GSSD results in low glutathione levels in erythrocytes and may present with hemolytic anemia alone or together with pyroglutamic aciduria, metabolic acidosis, and CNS damage. Five patients with pyroglutamic aciduria were studied. All presented with hemolytic anemia and metabolic acidosis. Two (brothers) also had Fanconi nephropathy, which is not seen in pyroglutamic aciduria. Molecular analyses of the GSS gene was performed in 3 patients. RT-PCR and heteroduplex analysis identified a homozygous deletion in 1 patient and a homozygous mutation in 2 others (brothers with Fanconi nephropathy). Sequencing of glutathione synthetase (GSS) cDNA from the first patient showed a 141-bp deletion corresponding to the entire exon 4, whilst the corresponding genomic DNA showed a G491 --> A homozygous splice site mutation. Sequencing of GSS cDNA from the Fanconi nephropathy patients showed a C847 --> T [ARG283 --> CYS] mutation in exon 9.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10450861     DOI: 10.1034/j.1399-0004.1999.550608.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  8 in total

1.  Trial of erythropoietin treatment in a boy with glutathione synthetase deficiency.

Authors:  J Sykut-Cegielska; A Jurecka; J Taybert; W Gradowska; M Pajdowska; E Pronicka
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

2.  Genotype, enzyme activity, glutathione level, and clinical phenotype in patients with glutathione synthetase deficiency.

Authors:  Runa Njålsson; Ellinor Ristoff; Katarina Carlsson; Andreas Winkler; Agne Larsson; Svante Norgren
Journal:  Hum Genet       Date:  2005-02-17       Impact factor: 4.132

3.  5-Oxoprolinuria in Heterozygous Patients for 5-Oxoprolinase (OPLAH) Missense Changes.

Authors:  Eduardo Calpena; Mercedes Casado; Dolores Martínez-Rubio; Andrés Nascimento; Jaume Colomer; Eva Gargallo; Angels García-Cazorla; Francesc Palau; Rafael Artuch; Carmen Espinós
Journal:  JIMD Rep       Date:  2012-07-06

4.  Kinetic properties of missense mutations in patients with glutathione synthetase deficiency.

Authors:  R Njålsson; K Carlsson; B Olin; B Carlsson; L Whitbread; G Polekhina; M W Parker; S Norgren; B Mannervik; P G Board; A Larsson
Journal:  Biochem J       Date:  2000-07-01       Impact factor: 3.857

5.  Human hereditary glutathione synthetase deficiency: kinetic properties of mutant enzymes.

Authors:  Runa Njålsson; Katarina Carlsson; Vikas Bhansali; Jia-Li Luo; Lennart Nilsson; Rudolf Ladenstein; Mary Anderson; Agne Larsson; Svante Norgren
Journal:  Biochem J       Date:  2004-07-15       Impact factor: 3.857

6.  Alternative RNA splicing in expression of the glutathione synthetase gene in human cells.

Authors:  Marie Uchida; Maki Sugaya; Taichi Kanamaru; Hisashi Hisatomi
Journal:  Mol Biol Rep       Date:  2009-08-12       Impact factor: 2.316

7.  Metabolomics analysis identifies glutamic acid and cystine imbalances in COVID-19 patients without comorbid conditions. Implications on redox homeostasis and COVID-19 pathophysiology.

Authors:  José C Páez-Franco; José L Maravillas-Montero; Nancy R Mejía-Domínguez; Jiram Torres-Ruiz; Karla M Tamez-Torres; Alfredo Pérez-Fragoso; Juan Manuel Germán-Acacio; Alfredo Ponce-de-León; Diana Gómez-Martín; Alfredo Ulloa-Aguirre
Journal:  PLoS One       Date:  2022-09-20       Impact factor: 3.752

8.  A case of severe glutathione synthetase deficiency with novel GSS mutations.

Authors:  H Xia; J Ye; L Wang; J Zhu; Z He
Journal:  Braz J Med Biol Res       Date:  2018-01-11       Impact factor: 2.590

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.